Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Lilly (LLY) delivered earnings and revenue surprises of +12.48% and +5.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lilly's daily obesity pill, orforglipron, shows positive results in late-stage trial, with patients losing nearly 12% of body ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Drug regulatory agencies in Germany and Australia have added warnings that atomoxetine can trigger violent or suicidal thoughts—sparking urgent concern over its long‑term use in children and adults.

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...